Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal malignancy with a high rate of recurrence and a dismal 5‐year survival rate. Contributing to the poor prognosis of PDAC is the lack of early detection, a complex network of signaling pathways and molecular mechanisms, a den...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.216 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589923821027328 |
|---|---|
| author | Heng‐Chung Kung Jun Yu |
| author_facet | Heng‐Chung Kung Jun Yu |
| author_sort | Heng‐Chung Kung |
| collection | DOAJ |
| description | Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal malignancy with a high rate of recurrence and a dismal 5‐year survival rate. Contributing to the poor prognosis of PDAC is the lack of early detection, a complex network of signaling pathways and molecular mechanisms, a dense and desmoplastic stroma, and an immunosuppressive tumor microenvironment. A recent shift toward a neoadjuvant approach to treating PDAC has been sparked by the numerous benefits neoadjuvant therapy (NAT) has to offer compared with upfront surgery. However, certain aspects of NAT against PDAC, including the optimal regimen, the use of radiotherapy, and the selection of patients that would benefit from NAT, have yet to be fully elucidated. This review describes the major signaling pathways and molecular mechanisms involved in PDAC initiation and progression in addition to the immunosuppressive tumor microenvironment of PDAC. We then review current guidelines, ongoing research, and future research directions on the use of NAT based on randomized clinical trials and other studies. Finally, the current use of and research regarding targeted therapy for PDAC are examined. This review bridges the molecular understanding of PDAC with its clinical significance, development of novel therapies, and shifting directions in treatment paradigm. |
| format | Article |
| id | doaj-art-90b90689a74444dead918259fa72ec61 |
| institution | Kabale University |
| issn | 2688-2663 |
| language | English |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | MedComm |
| spelling | doaj-art-90b90689a74444dead918259fa72ec612025-01-24T05:36:29ZengWileyMedComm2688-26632023-04-0142n/an/a10.1002/mco2.216Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical studyHeng‐Chung Kung0Jun Yu1Krieger School of Arts and Sciences Johns Hopkins University Baltimore Maryland USADepartments of Medicine and Oncology Johns Hopkins University School of Medicine Baltimore Maryland USAAbstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal malignancy with a high rate of recurrence and a dismal 5‐year survival rate. Contributing to the poor prognosis of PDAC is the lack of early detection, a complex network of signaling pathways and molecular mechanisms, a dense and desmoplastic stroma, and an immunosuppressive tumor microenvironment. A recent shift toward a neoadjuvant approach to treating PDAC has been sparked by the numerous benefits neoadjuvant therapy (NAT) has to offer compared with upfront surgery. However, certain aspects of NAT against PDAC, including the optimal regimen, the use of radiotherapy, and the selection of patients that would benefit from NAT, have yet to be fully elucidated. This review describes the major signaling pathways and molecular mechanisms involved in PDAC initiation and progression in addition to the immunosuppressive tumor microenvironment of PDAC. We then review current guidelines, ongoing research, and future research directions on the use of NAT based on randomized clinical trials and other studies. Finally, the current use of and research regarding targeted therapy for PDAC are examined. This review bridges the molecular understanding of PDAC with its clinical significance, development of novel therapies, and shifting directions in treatment paradigm.https://doi.org/10.1002/mco2.216neoadjuvant therapypancreatic ductal adenocarcinoma (PDAC)randomized clinical trialssignaling pathwaystargeted therapy |
| spellingShingle | Heng‐Chung Kung Jun Yu Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study MedComm neoadjuvant therapy pancreatic ductal adenocarcinoma (PDAC) randomized clinical trials signaling pathways targeted therapy |
| title | Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study |
| title_full | Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study |
| title_fullStr | Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study |
| title_full_unstemmed | Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study |
| title_short | Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study |
| title_sort | targeted therapy for pancreatic ductal adenocarcinoma mechanisms and clinical study |
| topic | neoadjuvant therapy pancreatic ductal adenocarcinoma (PDAC) randomized clinical trials signaling pathways targeted therapy |
| url | https://doi.org/10.1002/mco2.216 |
| work_keys_str_mv | AT hengchungkung targetedtherapyforpancreaticductaladenocarcinomamechanismsandclinicalstudy AT junyu targetedtherapyforpancreaticductaladenocarcinomamechanismsandclinicalstudy |